Shen Jie, Li Pei, Wang Yue, Yang Kailing, Li Yue, Yao Hui, Wang Qiang, Xiao Peigen, He Chunnian
Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
School of Medical Laboratory, Weifang Medical University, Weifang, China.
Front Plant Sci. 2022 Aug 17;13:951824. doi: 10.3389/fpls.2022.951824. eCollection 2022.
The genetic relationships among the species in genus remain unclear because of the variation in the number of species and complex trait. The usage of and its four substitute medicinal species (, , , and ) in traditional medicines make their specialized metabolism important in China, but interspecific genetic and chemical differences have rarely been reported for these species. In this study, the chloroplast genomes of four substitute species for were assembled, and comparative and phylogenetic analyses were performed with these species and other relatives. In addition, metabolomics analyses were performed and the contents of the main active compounds were determined to reveal the interspecific chemical diversity of and its four substitute species. The full lengths of their chloroplast genomes ranged from 151,574 to 151,816 bp with an average GC content of 38.34%, and a total of 113 genes were annotated. In the chloroplast genomes of and its four substitutes, one hypervariable region (-) is proposed as a potential DNA barcode. Phylogenetic analysis showed that the subdivision of the genus should be reconsidered. The metabolomics and content determination analyses showed that the four species exhibit a metabolism similar to that of in different parts. Except for the roots of , all parts of the substitute species showed high contents of baicalin. Genetic and chemical analyses of four substitute medicinal species for were performed here for the first time, and their pharmacophylogenetic relationships were further explored, providing a scientific basis for the subsequent development of the medicinal value and resource utilization of .
由于该属物种数量的变化和性状复杂，其物种间的遗传关系尚不清楚。[具体植物名称1]及其四种代用药用植物（[具体植物名称2]、[具体植物名称3]、[具体植物名称4]和[具体植物名称5]）在传统医学中的应用，使得它们的次生代谢在中国具有重要意义，但这些物种间的种间遗传和化学差异鲜有报道。在本研究中，组装了[具体植物名称1]的四种代用物种的叶绿体基因组，并与这些物种及其他[具体植物名称1]近缘种进行了比较和系统发育分析。此外，还进行了代谢组学分析并测定了主要活性化合物的含量，以揭示[具体植物名称1]及其四种代用物种的种间化学多样性。它们的叶绿体基因组全长在151,574至151,816 bp之间，平均GC含量为38.34%，共注释了113个基因。在[具体植物名称1]及其四种代用植物的叶绿体基因组中，一个高变区（[具体区域名称]）被提议作为潜在的DNA条形码。系统发育分析表明，[具体植物名称1]属的分类应重新考虑。代谢组学和含量测定分析表明，这四个物种在不同部位表现出与[具体植物名称1]相似的代谢。除了[具体植物名称1]的根以外，代用物种的所有部位都显示出高含量的黄芩苷。本研究首次对[具体植物名称1]的四种代用药用植物进行了遗传和化学分析，并进一步探索了它们的药物系统发育关系，为后续[具体植物名称1]药用价值的开发和资源利用提供了科学依据。
